Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, welcomes the European Court of Justice's (ECJ's) judgment today ruling that the European Commission did not have jurisdiction over Illumina's acquisition of GRAIL.

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its divestment plan for GRAIL from the European Commission (EC).

The European Commission has issued a Statement of Objections to Illumina and Grail on Monday, outlining the restorative measures it intends to adopt under the EU Merger Regulation.

C2i Genomics launches minimal residual disease test across Europe after clearing regulatory hurdles in the EU, UK, and Switzerland.

The European Union’s In Vitro Diagnostics Regulation (IVDR) is set to take effect May 26, 2022, but a recent effort to amend the transitional provisions of the new regulation may bring some relief.

DiaSorin said in Q3 it saw a strong recovery of non-COVID test sales including for latent tuberculosis and other infectious diseases as well as gastrointestinal infections.

Companies that have already registered their devices in the EU will still be able to sell their products in Great Britain until June 2023. From this point, they will be required to register their device for UK Conformity Assessed (UKCA) marking.

The European Commission has opened an investigation assess whether Illumina's decision to complete its acquisition of Grail is a breach of the “standstill obligation”